TBTanya M. Bisseling

Tanya M. Bisseling

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tanya M. Bisseling has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Fish Consumption and Colorectal Neoplasms among Lynch Syndrome Carriers

    by Marjolein T Bulbaai, Evertine Wesselink, Tanya M Bisseling, Jan Jacob Koornstra, Monique E van Leerdam, Loïc Le Marchand, Polly A Newcomb, N Jewel Samadder, Hanna Jm Schep-Wijnveen, Ellen Kampman, et al.

  • Open Access

    Continuous Remimazolam Administration by Gastroenterologists for Endoscopic Sedation

    by Tanya M. Bisseling, Angela van Zuuk, Michiel Vaneker, Hennie Hukker, Cariline Roosen, Jasmijn Olde, Marjolijn Duijvestein, Geert J. Bulte, Lucas T. van Eijk, Jörgen Bruhn

    Background and Objectives: Gastrointestinal (GI) endoscopy requires safe and effective sedation. Remimazolam, an ultra-short-acting benzodiazepine, may offer advantages over traditional sedatives like midazolam and propofol, including rapid onset, short half-life, and a favorable safety profile. This study evaluates the feasibility, safety, and patient satisfaction of continuous remimazolam infusion administered by trained gastroenterologists for GI endoscopy. Materials and Methods: This prospective registry included patients with ASA physical status I and II undergoing standard endoscopic procedures. Continuous remimazolam sedation was administered, with boluses given as needed. Vital signs were monitored, and patient satisfaction was assessed before and after the procedure using standardized questionnaires. Results: A total of 159 procedures were performed in 141 patients. Sedation was successful in all patients, with a mean induction dose of 7.1 mg and total infusion of 15.1 mg. Recovery time averaged 3.3 min. Adverse events, including transient hypotension and hypoxia, occurred in 11.3% of patients but were easily managed. Most patients (97%) reported sufficient comfort, with an average satisfaction score of 8.1/10. Conclusions: Continuous remimazolam infusion administered by trained gastroenterologists is a safe and effective alternative to traditional propofol sedation for GI endoscopy. It offers stable sedation, rapid recovery and high patient satisfaction, potentially reducing anesthesiology workload and improving procedural efficiency. Further studies are needed to confirm these findings in broader patient populations.


  • Open Access

    Endoscopic surveillance for colorectal cancer and its precursor lesions in Lynch syndrome; time for some policy shifts?

    by Romy N Kuipers, Marissa F Burggraaff, Michiel Hj Maas, Dorien Tj van der Biessen – van Beek, Mariëtte Ca van Kouwen, Tanya M Bisseling

    Background: While numerous studies have demonstrated variations in colorectal cancer (CRC) incidence among Lynch Syndrome (LS)-associated germline pathogenic variant (gPV) carriers, limited data are available regarding tailoring surveillance and treatment strategies. The main goal of this study was to estimate whether personalised care could be offered based on the different gPVs (MLH1, MSH2, MSH6 or PMS2). Additionally, the outcome from patient-shared care for early (T1) CRC was investigated. Methods: The study is performed as a single centre retrospective analysis of our cohort of patients with a LS-associated gPV in MLH1, MSH2, MSH6 or PMS2. Colon surveillance data from between January 1978 to February 2024 were collected. Analyses were performed to identify differences in incidence of precursor lesions and CRC between the different variants and treatment variation for CRC in LS. Results: From a cohort of 621 LS individuals 496 (133 MLH1, 107 MSH2, 180 MSH6 and 76 PMS2) could be included in this study. Analyses revealed that, despite adequate surveillance intervals and lower adenoma incidence, individuals with a gPV in MLH1 or MSH2 have higher CRC incidences compared to MSH6 or PMS2. Most detected CRC lesions were early stage (T1) CRCs. Treatment for T1 CRC varied considerably; in 68% of the cases deviating from a subtotal colectomy, with nearly equivalent recurrence rates. Discussion: Based on higher precursor lesion detection and lower CRC incidences in LS individuals with a gPV in MSH6 or PMS2 under biannual endoscopic surveillance, this study supports the potential for extended surveillance intervals in the latter group. As treatment for the detected T1 CRCs varied considerably with nearly equivalent recurrence rates, in selected cases less invasive interventions for LS individuals could be considered.


  • Open Access

    Current advances and challenges in Managing Hereditary Diffuse Gastric Cancer (HDGC): a narrative review

    by L. van der Sluis, J.M. van Dieren, R.S. van der Post, T.M. Bisseling

    More than 25 years ago, CDH1 pathogenic variants (PVs) were identified as the primary cause of hereditary diffuse gastric cancer (HDGC), an inherited cancer syndrome that increases the lifetime risk of developing diffuse gastric cancer (DGC) and lobular breast cancer (LBC). Since DGC is associated with a poor prognosis, a prophylactic total gastrectomy (PTG) is currently the gold standard for reducing the risk of DGC in CDH1 PV carriers. However, as germline genetic testing becomes more widespread, many CDH1 PV carriers have been identified, including in families with lower penetrance levels or without a history of gastric cancer (GC). When including these families, recent findings suggest that the cumulative lifetime risk of developing advanced DGC is much lower than previously thought and is now estimated to be 13–19%. This lower risk, combined with the fact that around one third of the CDH1 PV carriers decline PTG due to potential lifelong physical and psychological consequences, raises critical questions about the current uniformity in recommending PTG to all CDH1 PV carriers. As a result, there is a growing need to consider alternative strategies, such as endoscopic surveillance. However, despite the currently lower estimated risk of infiltrative (advanced) DGC, almost every PTG specimen shows the presence of small low-stage (pT1a) signet ring cell (SRC) lesions of which the behaviour is unpredictable but often are considered indolent or premalignant stages of DGC. Therefore, the primary goal of surveillance should be to identify atypical, deeper infiltrating lesions rather than every SRC lesion. Understanding the progression from indolent to more infiltrative lesions, and recognizing their endoscopic and histological features, is crucial in deciding the most suitable management option for each individual.


  • Shifting perceptions on endoscopic surveillance and timing of prophylactic gastrectomy for hereditary diffuse gastric cancer

    by Jolanda M van Dieren, Rachel S van der Post, Tanya M Bisseling

    Hereditary diffuse-type gastric cancer (HDGC) is a rare condition that in most cases is caused by a pathogenic germline variant in the CDH1 gene and rarely in the CTNNA1 gene. In the early years after identification of CDH1 the lifetime risk to develop diffuse-type gastric cancer was estimated at 70 per cent1. These estimates resulted from previous publications on families with a high frequency of affected persons, whereas non-affected families were less likely to be included in these early publications (also known as ascertainment bias). This high lifetime risk led to the (current) advice for all mutation carriers to undergo prophylactic total gastrectomy. Over the years it became apparent that not all likely pathogenic and pathogenic (LP/P) variants in CDH1 harbor the same cancer risk. About 410 different LP/P variants have been documented. Nowadays it is known that about a fifth of these are missense variants, which seldom appear to segregate with the phenotypic HDGC2. Not only might the germline variant cause heterogeneity in phenotype, but also within families there is a wide variation of cancer risk. Currently, the lifetime risk estimations for gastric cancer are adjusted to 33 per cent for women and 40 per cent for men3. Consequently, some mutation carriers express doubt about undergoing prophylactic gastrectomy. Some prefer to postpone surgery and undergo annual gastroscopic surveillance until (early) invasive gastric cancer is detected.


    • 8 February 2023
      • Vol. 167

    [The influence of ultra-processed food on cardiovascular disease: how "why do things the hard way?" makes our brains soft].

    by Tanya M Bisseling

    Buying and consuming ultra-processed food makes life easy. Nowadays, there is more and more prove that the consumption of this food is associated with morbidity and mortality, e.g. cardiovascular disease, diabetes, neurocognitive diseases and cancer. Recently, Bonaccio et al. strenghtened this in a large prospective cohort for cardiovascular disease. They used among others the 'Nutri-Score' for their analysis. However, the reliability of this score remains under debate, and therefore, it is not the best to use as label for consumers. In short: although consumption of ultra-processed food is a risk factor for cardiovascular and other diseases, for consumers is remains difficult to recognize the healthiest food in the supermarket. What's in this for you, doc? Keep this in mind during your all-day practice and guide your patients to healthier foods during their consultation with you.

  • Open Access

    Detection and Yield of Colorectal Cancer Surveillance in Adults with PTEN Hamartoma Tumour Syndrome

    by Meggie M. C. M. Drissen, Janet R. Vos, Dorien T. J. van der Biessen-Van Beek, Rachel S. van der Post, Iris D. Nagtegaal, Mariëtte C. A. van Kouwen, Tanya M. Bisseling, Nicoline Hoogerbrugge

    Colorectal cancer surveillance (CCS) with colonoscopy every five years is advised for PTEN Hamartoma Tumour Syndrome (PHTS) patients aged ≥40 due to an increased colorectal cancer (CRC) risk. However, data to support CCS guidelines are scarce and available CRC risks are low (0–5% at age 50) and likely overestimated. We aimed to assess the detection and yield of CCS for PHTS patients without a CRC history. A retrospective cohort study including PHTS patients aged ≥40 with CCS at a PHTS expertise centre between 2011 and 2022. Adenomas with a ≥10 mm size, (tubulo)villous histology, or high-grade dysplasia were considered advanced. During 67 follow-up years, 37 patients (median age 47 years) underwent 61 colonoscopies. CCS yielded no CRCs. Adenomas were diagnosed in 13/37 (35%) patients during 23/100 colonoscopies (95% CI: 14–36), including one advanced adenoma. Baseline adenoma detection rates were similar to follow-up and higher in patients aged above 50 (50/100, 95% CI: 24–76) vs. age 50 or below (11/100, 95% CI: 3–30; p = 0.021). The low CRC and advanced adenoma yield allow for a more personalised surveillance program. Following our findings combined with literature on CRC risk and progression, we suggest starting CCS at age 40 with variable follow-up intervals between 1 and 10 years depending on previous colonoscopy findings.


  • International Delphi consensus guidelines for follow-up after prophylactic total gastrectomy: the Life after Prophylactic Total Gastrectomy (LAP-TG) study

    by Geoffrey Roberts, Patrick R. Benusiglio, Tanya Bisseling, Daniel Coit, Jeremy L. Davis, Sam Grimes, Theresa A. Guise, Richard Hardwick, Kirsty Harris, Paul Furman Mansfield, et al.

    Background Prophylactic total gastrectomy (PTG) remains the only means of preventing gastric cancer for people with genetic mutations predisposing to Hereditary Diffuse Gastric Cancer (HDGC), mainly in the CDH1 gene. The small but growing cohort of people undergoing PTG at a young age are expected to have a life-expectancy close to the general population, however, knowledge of the long-term effects of, and monitoring requirements after, PTG is limited. This study aims to define the standard of care for follow-up after PTG. Methods Through a combination of literature review and two-round Delphi consensus of major HDGC/PTG units and physicians, and patient advocates, we produced a set of recommendations for follow-up after PTG. Results There were 42 first round, and 62 second round, responses from clinicians, allied health professionals and patient advocates. The guidelines include recommendations for timing of assessments and specialties involved in providing follow-up, micronutrient supplementation and monitoring, bone health and the provision of written information. Conclusion While the evidence supporting the guidelines is limited, expert consensus provides a framework to best manage people following PTG, and could support the collection of information on the long-term effects of PTG.


  • Open Access

    Diet quality and colorectal tumor risk in persons with Lynch syndrome

    by Anouk H. Eijkelboom, Jesca G.M. Brouwer, Hans F.A. Vasen, Tanya M. Bisseling, Jan J. Koornstra, Ellen Kampman, Fränzel J.B. van Duijnhoven


  • Open Access

    Diagnostic Accuracy of Stool Tests for Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors

    by Berbel Ykema, Lisanne Rigter, Manon Spaander, Leon Moons, Tanya Bisseling, Berthe Aleman, Jan Paul de Boer, Pieternella Lugtenburg, Cecile Janus, Eefke Petersen, et al.

    Background: Hodgkin lymphoma (HL) survivors have an increased colorectal cancer (CRC) risk. Diagnostic accuracy of quantitative fecal immunochemical testing (FIT, OC Sensor) and/or a multi-target stool DNA test (mt-sDNA, Cologuard®) for advanced neoplasia (AN) was evaluated. Methods: 101 HL survivors underwent a surveillance colonoscopy and were asked to perform two stool tests (FIT and mt-sDNA). Advanced adenoma (AA), advanced serrated lesion (ASL), and AN (AA, ASL, CRC) were evaluated. Sensitivity, specificity, and area under the curve (AUC) for AN were calculated for different FIT cut-offs and mt-sDNA with colonoscopy as reference. Results: FIT and mt-sDNA were analyzed in 73 (72%) and 82 (81%) participants, respectively. AN was detected in 19 (26%) and 22 (27%), respectively. AN sensitivities for FIT cut-off of 10 ug Hb/g feces (FIT10) and mt-sDNA were 37% (95% confidence interval (CI): 16–62) and 68% (95% CI: 45–86), with corresponding specificities of 91% (95% CI: 80–97) and 70% (95% CI: 57–86), respectively. AUC for FIT was 0.68 (95% CI: 0.54–0.82) and for mt-sDNA 0.76 (95% CI: 0.63–0.89). Conclusions: In HL survivors, mt-sDNA showed highest sensitivity but with relatively low specificity for AN. Cost-effectiveness analyses is necessary to determine the optimal surveillance strategy.